Evaluation of the fragility of pivotal trials used to support US Food and Drug Administration approval for plaque psoriasis - 11/01/21
Abstract |
Background |
Over the last 5 years, there has been a rapid growth in the number of clinical trials used to support a US Food and Drug Administration (FDA) approval for systemic therapies with labeled indications for plaque psoriasis.
Objective |
We aim to evaluate the fragility of clinical trial data used to support FDA approval of therapies for psoriasis.
Methods |
We reviewed the primary endpoints of the pivotal trials of all systemic medications with a labeled indication for plaque psoriasis available from Drugs@FDA.
Results |
Sixty-nine clinical trial primary endpoints met inclusion criteria and were assessed for robustness, yielding a median fragility index of 72 and a median fragility quotient of 0.19.
Limitations |
Efficacy and statistical analysis data for several approved medications were not available on the product label or on Drugs@FDA.
Conclusions |
When compared with randomized controlled trials for FDA approval across various diseases, pivotal trials in psoriasis appear quite robust to changes in outcomes.
Le texte complet de cet article est disponible en PDF.Key words : biologics, fragility index, fragility quotient, Physician Global Assessment, pivotal trials, psoriasis, Psoriasis Area and Severity Index
Abbreviations used : FDA, FI, FQ, MFI, MFQ, PASI, PGA, RCT
Plan
| Funding sources: None. |
|
| Dr Miller has received honoraria for participating on advisory boards for Pfizer, Merck, Regeneron, and Sanofi Genzyme. |
|
| Reprints not available from the authors. |
Vol 84 - N° 2
P. 354-360 - février 2021 Retour au numéro
Article précédent
- Oral forms of secondary syphilis: An illustration of the pitfalls set by the great imitator
- Alexandre Lampros, Vannina Seta, Phillippe Gerhardt, Camille Isnard, Corinne Husson, Nicolas Dupin
- Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinoma
- Ashley Wysong, Jason G. Newman, Kyle R. Covington, Sarah J. Kurley, Sherrif F. Ibrahim, Aaron S. Farberg, Anna Bar, Nathan J. Cleaver, Ally-Khan Somani, David Panther, David G. Brodland, John Zitelli, Jennifer Toyohara, Ian A. Maher, Yang Xia, Kristin Bibee, Robert Griego, Darrell S. Rigel, Kristen Meldi Plasseraud, Sarah Estrada, Lauren Meldi Sholl, Clare Johnson, Robert W. Cook, Chrysalyne D. Schmults, Sarah T. Arron
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?